Kringle Pharma, Inc. (4884.T)
JPY 818.0
(1.74%)
JPY 818.0
(1.74%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -888.76 Million JPY | -108.55% |
| 2022 | -426.16 Million JPY | -19.08% |
| 2021 | -357.88 Million JPY | -108.55% |
| 2020 | -171.6 Million JPY | 53.84% |
| 2019 | -371.74 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -212.97 Million JPY | -7.48% |
| 2024 Q1 | -168.59 Million JPY | 37.16% |
| 2024 Q2 | -198.15 Million JPY | -17.53% |
| 2023 Q4 | -268.27 Million JPY | 12.2% |
| 2023 FY | -888.76 Million JPY | -108.55% |
| 2023 Q3 | -305.55 Million JPY | -94.04% |
| 2023 Q1 | -157 Million JPY | -264.62% |
| 2023 Q2 | -157.46 Million JPY | -0.3% |
| 2022 FY | -426.16 Million JPY | -19.08% |
| 2022 Q4 | -43.05 Million JPY | 0.0% |
| 2021 FY | -357.88 Million JPY | -108.55% |
| 2020 FY | -171.6 Million JPY | 53.84% |
| 2019 FY | -371.74 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 248.916% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -78.873% |
| GNI Group Ltd. | 13.1 Billion JPY | 106.78% |
| Linical Co., Ltd. | 725.72 Million JPY | 222.466% |
| Trans Genic Inc. | 89.43 Million JPY | 1093.741% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 37.672% |
| Soiken Holdings Inc. | -610 Million JPY | -45.697% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -15.014% |
| AnGes, Inc. | -11.96 Billion JPY | 92.574% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 20.703% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 90.67% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 952.129% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -2.817% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 20.432% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 29.575% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -11.296% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -163.442% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 26.254% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 33.456% |
| PeptiDream Inc. | 6.77 Billion JPY | 113.122% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 53.95% |
| Ribomic Inc. | -1.11 Billion JPY | 20.376% |
| SanBio Company Limited | -4.53 Billion JPY | 80.419% |
| Healios K.K. | -3.37 Billion JPY | 73.697% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 23.056% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 36.221% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 36.653% |
| StemRIM | -2.07 Billion JPY | 57.189% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 172.76% |
| FunPep Company Limited | -994 Million JPY | 10.587% |
| Stella Pharma Corporation | -760.3 Million JPY | -16.896% |
| TMS Co., Ltd. | -943.25 Million JPY | 5.777% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -14.621% |
| Cuorips Inc. | -588.48 Million JPY | -51.025% |
| K Pharma,Inc. | 366.05 Million JPY | 342.793% |
| Takara Bio Inc. | 3 Billion JPY | 129.596% |
| ReproCELL Incorporated | -409.29 Million JPY | -117.146% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 8133.644% |
| StemCell Institute Inc. | 413.75 Million JPY | 314.802% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 715.03% |
| CellSeed Inc. | -697.77 Million JPY | -27.371% |